Acumen Pharmaceuticals at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Acumen Pharmaceuticals takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on what participants and study partners in the ALTITUDE-AD trial expect from treatment and how they experience care in early Alzheimer's disease.
| Organization | CTAD 2026 Attendance |
|---|---|
Acumen Pharmaceuticals Newton, Massachusetts | ◇Silver Sponsor |
Develops sabirnetug, an antibody targeting toxic amyloid-beta oligomers, tested in the Phase 2 ALTITUDE-AD trial in early Alzheimer's disease. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue |
Instantly find 20 buyers from Acumen Pharmaceuticals
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction